Portal Hypertension - 2018 Pipeline Insights: Cumberland Pharmaceuticals and Conatus Pharmaceuticals Dominate the Market - ResearchAndMarkets.com

July 30, 2018

DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “Portal Hypertension- Pipeline Insights, 2018” report has been added to ResearchAndMarkets.com’s offering.

This report outlays comprehensive insights of present scenario and growth prospects across Portal Hypertension.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 3+ active products along with 3+ companies involved. Cumberland Pharmaceuticals and Conatus Pharmaceuticals are among the major drug developers as per the current pipeline scenario.

Products covered by Phase

Phase II Unknown Stage Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Portal Hypertension

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for Portal Hypertension The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.


Provides an overview of therapeutic pipeline activity for Portal Hypertension across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of Portal Hypertension therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Portal Hypertension

Key Topics Covered

Executive Summary Disease Overview Introduction Causes Pathophysiology Symptoms Diagnosis Management and Treatment Pipeline Therapeutics (Active Products) Pipeline Therapeutics (Inactive Products) Comparative Analysis Mid Stage Products (Phase II) Comparative Analysis Ifetroban: Cumberland Pharmaceuticals Product Description Research and Development Product Development Activities The list continues.. Unknown Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Inactive Products Comparative Analysis Appendix

Companies Featured

Adare Pharmaceuticals Conatus Pharmaceuticals Cumberland Pharmaceuticals Ferring Pharmaceuticals Gilead Sciences Intercept Pharmaceuticals Mallinckrodt Pharmaceuticals Mezzion Pharma Novartis ONO Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/sqm5rr/portal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005589/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 12:31 PM/DISC: 07/30/2018 12:31 PM


Update hourly